King's College London

Research portal

Proteomics in aortic aneurysm - What have we learnt so far?

Research output: Contribution to journalArticle

Standard

Proteomics in aortic aneurysm - What have we learnt so far? / Abdulkareem, Nada; Skroblin, Philipp; Jahangiri, Marjan; Mayr, Manuel.

In: Proteomics Clinical Applications, Vol. 7, No. 7-8, 01.08.2013, p. 504-515.

Research output: Contribution to journalArticle

Harvard

Abdulkareem, N, Skroblin, P, Jahangiri, M & Mayr, M 2013, 'Proteomics in aortic aneurysm - What have we learnt so far?', Proteomics Clinical Applications, vol. 7, no. 7-8, pp. 504-515. https://doi.org/10.1002/prca.201300016

APA

Abdulkareem, N., Skroblin, P., Jahangiri, M., & Mayr, M. (2013). Proteomics in aortic aneurysm - What have we learnt so far? Proteomics Clinical Applications, 7(7-8), 504-515. https://doi.org/10.1002/prca.201300016

Vancouver

Abdulkareem N, Skroblin P, Jahangiri M, Mayr M. Proteomics in aortic aneurysm - What have we learnt so far? Proteomics Clinical Applications. 2013 Aug 1;7(7-8):504-515. https://doi.org/10.1002/prca.201300016

Author

Abdulkareem, Nada ; Skroblin, Philipp ; Jahangiri, Marjan ; Mayr, Manuel. / Proteomics in aortic aneurysm - What have we learnt so far?. In: Proteomics Clinical Applications. 2013 ; Vol. 7, No. 7-8. pp. 504-515.

Bibtex Download

@article{7a362ea70cce4204a5219354788af614,
title = "Proteomics in aortic aneurysm - What have we learnt so far?",
abstract = "Aortic aneurysm is a deceptively indolent disease that can cause severe complications such as aortic rupture and dissection. In the normal aorta, vascular smooth muscle cells within the medial layer produce and sustain the extracellular matrix (ECM) that provides structural support but also retains soluble growth factors and regulates their distribution. Although the ECM is an obvious target to identify molecular processes leading to structural failure within the vessel wall, an in-depth proteomics analysis of this important sub-proteome has not been performed. Most proteomics analyses of the vasculature to date used homogenized tissue devoid of spatial information. In such homogenates, quantitative proteomics comparisons are hampered by the heterogeneity of clinical samples (i.e. cellular composition) and the dynamic range limitations stemming from highly abundant cellular proteins. An unbiased proteomics discovery approach targeting the ECM instead of the cellular proteome may decipher the complex, multivalent signals that are presented to cells during aortic remodelling. A better understanding of the ECM in healthy and diseased vessels will provide important pathogenic insights and has potential to reveal novel biomarkers. ",
keywords = "Aortic aneurysm, Biomarkers, Clinical complications",
author = "Nada Abdulkareem and Philipp Skroblin and Marjan Jahangiri and Manuel Mayr",
note = "{\circledC} 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.",
year = "2013",
month = "8",
day = "1",
doi = "10.1002/prca.201300016",
language = "English",
volume = "7",
pages = "504--515",
journal = "Proteomics Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "7-8",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Proteomics in aortic aneurysm - What have we learnt so far?

AU - Abdulkareem, Nada

AU - Skroblin, Philipp

AU - Jahangiri, Marjan

AU - Mayr, Manuel

N1 - © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Aortic aneurysm is a deceptively indolent disease that can cause severe complications such as aortic rupture and dissection. In the normal aorta, vascular smooth muscle cells within the medial layer produce and sustain the extracellular matrix (ECM) that provides structural support but also retains soluble growth factors and regulates their distribution. Although the ECM is an obvious target to identify molecular processes leading to structural failure within the vessel wall, an in-depth proteomics analysis of this important sub-proteome has not been performed. Most proteomics analyses of the vasculature to date used homogenized tissue devoid of spatial information. In such homogenates, quantitative proteomics comparisons are hampered by the heterogeneity of clinical samples (i.e. cellular composition) and the dynamic range limitations stemming from highly abundant cellular proteins. An unbiased proteomics discovery approach targeting the ECM instead of the cellular proteome may decipher the complex, multivalent signals that are presented to cells during aortic remodelling. A better understanding of the ECM in healthy and diseased vessels will provide important pathogenic insights and has potential to reveal novel biomarkers. 

AB - Aortic aneurysm is a deceptively indolent disease that can cause severe complications such as aortic rupture and dissection. In the normal aorta, vascular smooth muscle cells within the medial layer produce and sustain the extracellular matrix (ECM) that provides structural support but also retains soluble growth factors and regulates their distribution. Although the ECM is an obvious target to identify molecular processes leading to structural failure within the vessel wall, an in-depth proteomics analysis of this important sub-proteome has not been performed. Most proteomics analyses of the vasculature to date used homogenized tissue devoid of spatial information. In such homogenates, quantitative proteomics comparisons are hampered by the heterogeneity of clinical samples (i.e. cellular composition) and the dynamic range limitations stemming from highly abundant cellular proteins. An unbiased proteomics discovery approach targeting the ECM instead of the cellular proteome may decipher the complex, multivalent signals that are presented to cells during aortic remodelling. A better understanding of the ECM in healthy and diseased vessels will provide important pathogenic insights and has potential to reveal novel biomarkers. 

KW - Aortic aneurysm

KW - Biomarkers

KW - Clinical complications

UR - http://www.scopus.com/inward/record.url?scp=84881503112&partnerID=8YFLogxK

U2 - 10.1002/prca.201300016

DO - 10.1002/prca.201300016

M3 - Article

C2 - 23670877

AN - SCOPUS:84881503112

VL - 7

SP - 504

EP - 515

JO - Proteomics Clinical Applications

JF - Proteomics Clinical Applications

SN - 1862-8346

IS - 7-8

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454